Campbell & CO Investment Adviser LLC Takes Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Campbell & CO Investment Adviser LLC acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMRFree Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 31,097 shares of the company’s stock, valued at approximately $792,000. Campbell & CO Investment Adviser LLC owned approximately 0.06% of Kymera Therapeutics as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in KYMR. Quest Partners LLC bought a new stake in shares of Kymera Therapeutics in the 4th quarter worth about $78,000. Arizona State Retirement System bought a new position in shares of Kymera Therapeutics in the 3rd quarter valued at about $142,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Kymera Therapeutics by 352.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,423 shares of the company’s stock valued at $164,000 after purchasing an additional 5,002 shares during the last quarter. Hsbc Holdings PLC bought a new position in shares of Kymera Therapeutics in the 3rd quarter valued at about $185,000. Finally, Exchange Traded Concepts LLC boosted its stake in shares of Kymera Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 7,359 shares of the company’s stock valued at $187,000 after purchasing an additional 1,866 shares during the last quarter.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on KYMR shares. Oppenheimer reduced their target price on shares of Kymera Therapeutics from $53.00 to $52.00 and set an “outperform” rating on the stock in a research note on Friday, May 3rd. JPMorgan Chase & Co. lifted their price objective on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Piper Sandler lifted their price objective on shares of Kymera Therapeutics from $39.00 to $56.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Stifel Nicolaus lifted their price target on shares of Kymera Therapeutics from $35.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, February 23rd. Finally, Truist Financial lifted their price target on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $42.70.

Read Our Latest Stock Report on KYMR

Insider Transactions at Kymera Therapeutics

In other news, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $42.85, for a total value of $1,812,640.70. Following the sale, the insider now owns 4,925,812 shares of the company’s stock, valued at $211,071,044.20. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Bruce Booth sold 71,764 shares of the business’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $40.46, for a total transaction of $2,903,571.44. Following the transaction, the director now directly owns 806,697 shares in the company, valued at $32,638,960.62. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of the business’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $42.85, for a total transaction of $1,812,640.70. Following the transaction, the insider now owns 4,925,812 shares in the company, valued at $211,071,044.20. The disclosure for this sale can be found here. Insiders have sold a total of 419,595 shares of company stock valued at $17,650,436 over the last 90 days. 15.82% of the stock is owned by corporate insiders.

Kymera Therapeutics Price Performance

Shares of KYMR stock opened at $32.87 on Friday. The company’s fifty day simple moving average is $35.44 and its 200-day simple moving average is $32.88. Kymera Therapeutics, Inc. has a 12 month low of $9.60 and a 12 month high of $45.31.

Kymera Therapeutics (NASDAQ:KYMRGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04. The business had revenue of $10.30 million for the quarter, compared to analyst estimates of $14.24 million. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 31.92%. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.70) earnings per share. As a group, sell-side analysts forecast that Kymera Therapeutics, Inc. will post -2.86 EPS for the current year.

About Kymera Therapeutics

(Free Report)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Featured Stories

Institutional Ownership by Quarter for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.